Abstract
AbstractA series of novel 1‐triazolylpyranopyrazole derivatives has been designed and synthesized using microwave irradiation, with the purpose of obtaining repositioned pharmaceutics. The newly synthesized 1‐triazolylpyranopyrazoles (7 a–7 n), along with their precursor alkyne (5), have been screened for their in‐vitro anti‐tumor activity against Hep3B and HEK cell lines. The majority of triazolylpyranopyrazoles elicited outstanding anti‐cancer activity on Hep3B cell lines even at concentrations as low as 25μg/mL. Further, molecular docking of these active compounds against Topoisomerase IIa substantiated a plausible target site for the compounds inhibiting Hep3B cells effectively. The biological assay results for the triazolylpyranopyrazole even surpassed the activity of the reference drug i. e. Doxorubicin, thereby appearing to be potent anticancer agents.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
